Topotecan as second-line therapy for ovarian cancer: Dosage versus toxicity

Oncologist

Volumn 10, Issue 9, 2005, Pages 695-697

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow toxicity; Ovarian cancer; Second line therapy; Topotecan

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; TOPOTECAN;

ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION;

ANTINEOPLASTIC AGENTS; BONE MARROW; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 27644502351     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-9-695     Document Type: Article

References (17)

1. Armstrong DK, Spriggs D, Levin J et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The Oncologist 2005;10:686-694.
2. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2000;18:1062-1067.
3. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322.
4. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian caner. Gynecol Oncol 2001;83:257-262.
5. Gronlund B, Hansen HH, Hogdall C et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian cancer. Cancer 2002;95:1656-1662.
6. Markman M, DeMarco J. Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval. Cancer 2003;98:215-218.
7. Rose PG, Maxson JH, Fusco N et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323-328.
8. Campos SM, Penson RT, Mays AR et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001;81:206-212.
9. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369-372.
10. Dizon DS, Dupont J, Anderson S et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003;91:584-590.
11. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-211.
12. Markman M, Kennedy A, Webster K et al. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 1997;65:434-436.
13. von Gruenigen VE, Karlen JR, Waggoner SE. A case of chronic paclitaxel administration in ovarian cancer. Gynecol Oncol 2003;89:532-535.
14. Rohl J, Kushner D, Markman M. Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol 2001;81:201-205.
15. Zanotti KM, Belinson JL, Kennedy AW et al. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 2000;79:211-215.
16. Uyar D, Kulp B, Peterson G et al. Cardiac safety profile of prolonged (≥ 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 2004;94:147-151.
17. Markman M, Bookman MA. Second-line treatment of ovarian cancer. The Oncologist 2000;5:26-35.